What is HC Wainwright’s Estimate for Curis Q1 Earnings?

Curis, Inc. (NASDAQ:CRIS) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Curis in a research report issued on Monday, March 31st. HC Wainwright analyst E. White expects that the biotechnology company will post earnings per share of ($1.39) for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share. HC Wainwright also issued estimates for Curis’ Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($2.98) EPS and FY2027 earnings at ($2.87) EPS.

Separately, StockNews.com initiated coverage on shares of Curis in a research report on Saturday, March 29th. They set a “hold” rating on the stock.

Curis Price Performance

CRIS opened at $1.33 on Thursday. Curis has a 1 year low of $1.33 and a 1 year high of $17.49. The company has a market capitalization of $11.26 million, a price-to-earnings ratio of -0.17 and a beta of 3.49. The firm’s fifty day moving average price is $2.89 and its two-hundred day moving average price is $3.80.

Curis (NASDAQ:CRIS) last announced its earnings results on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.11. The company had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. M28 Capital Management LP raised its stake in shares of Curis by 23.5% during the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock worth $1,594,000 after purchasing an additional 99,108 shares during the period. Bleichroeder LP increased its holdings in Curis by 1,982.2% during the fourth quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock worth $1,593,000 after buying an additional 495,540 shares during the last quarter. CM Management LLC raised its position in Curis by 83.3% in the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after acquiring an additional 100,000 shares during the period. Alyeska Investment Group L.P. purchased a new position in Curis in the fourth quarter valued at about $607,000. Finally, Samsara BioCapital LLC bought a new position in shares of Curis during the 4th quarter valued at approximately $607,000. Hedge funds and other institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.